Pitfalls in the diagnostic biopsy (Davide Gigliano)
How to stratify disease after neoadjuvant approach (Andre Coelho)
Is there any situation that radiologic exams can "replace" biopsy? (Pedro Martins)
Hereditary and GIST: when to suspect (Rita Quental)
Patients eligible only for surveillance (Diana Freitas)
Surgery: radicality according to location (Marco Fiore)
Adjuvant imatinib treatment: for whom, what dose and for how long? (Ana Ferreira)
A different multi kinase inhibitor: ripretinib (Joana Mendonça)
What we already know about mechanisms of resistance and the role of ctDNA (Cesar Serrano)
The role of surgery in first relapse and in subsequent progressions (José António Gonzalez)
Mutational status' implications in relapse approach (Maria Cassiano)
Is there a place for imatinib 800mg in the era of new TKIs? (Cecilia Melo Alvim )
New strategies of systemic treatment in advanced disease (Claudia Valverde)
Are there new places for radiotherapy? (Artur Aguiar)
SDH deficient GIST (Daniela Almeida)
GIST with 842V PDGFRA mutation (Cesar Serrano)
Quadruple negative GIST (Javier M. Broto)
Case 1: Life threatening GIST (discussing situation recognition and approach) (Catarina Baia)
Case 2: Long responders (discussing the characteristics of these patients,
radiologic surveillance, possibility to stop treatment) (Michelle Silva)